The BIOSECURE Act aims to reduce American dependency on Chinese biopharma manufacturing. With over 80% of US biopharma companies working with a Chinese CDMO, this bipartisan bill is set to trigger significant shifts across the industry.

The disruption presents an opportunity for both companies and investors to build resilience and capitalize on contracts diverted from China. Companies are already making moves to de-risk their overseas partners and boost their biologics manufacturing capacity.

In this paper, we discuss the actions companies have been taking in response to the bill, the impact it will have on different stakeholders, and strategic moves companies and investors should take to turn disruption into advantage.

Read the Full Paper Here